Drug intelligence / Profile preview

Zicam

Development stage
Phase 3
Lead developer
Matrixx Initiatives
Administration
Oral, Intranasal
01

Overview

**Zicam** is a branded line of over-the-counter homeopathic products primarily marketed to reduce the duration and severity of common cold symptoms, such as nasal congestion. Its key active ingredients are **zincum aceticum** (zinc acetate, 2X dilution) and **zincum gluconicum** (zinc gluconate, 1X or 2X dilution), available in formats including oral rapidmelts, lozenges, medicated drops, oral mist, and previously nasal gels/swabs (discontinued due to safety issues). Originally developed by Matrixx Initiatives and now owned by **Church & Dwight**, Zicam leverages zinc's potential antiviral effects against rhinoviruses by targeting ICAM-1 receptors, though labeled homeopathic to bypass standard FDA efficacy testing. Intranasal versions were recalled in 2009 after over 130 reports of permanent anosmia (loss of smell) from zinc-induced olfactory epithelium damage; current oral products remain available but lack robust clinical evidence of effectiveness beyond placebo.[1][2][4][7]

Brand names
Zicam
Other names
Zicam Cold Remedy
02

Targets

ICAM1 (Intercellular Adhesion Molecule 1)

Beyond the preview

Go deeper on Zicam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zicam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call